Drug: Udenyca (pegfilgrastim-cbqv)

Manufacturer: Coherus BioSciences

Route of Administration: Subcutaneous

Site of Care: Outpatient

Approved Indication:

• to decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of febrile neutropenia
• to increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome)

Disease: neutropenia associated with myelosuppressive anti-cancer therapy, hematopoietic syndrome of acute radiation syndrome

Therapeutic Area: Hematology, Oncology

Enrollment Form Link: Coherus Solutions

Phone Number: 1-844-483-3692

Fax Number: 1-877-226-6370

Product Website: udenyca.com